Skin Diseases, Infectious Clinical Trial
Official title:
Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus
The proposed study is a prospective, open-label, randomized, multi-center trial of ceftaroline versus vancomycin for the treatment of ABSSSI in patients documented or at risk for MRSA. Patients admitted to the Detroit Medical Center, Henry Ford Hospital, or St. John Medical Center in Detroit Michigan with a documented ABSSSI between April 2012 and November 2015 will be evaluated for inclusion. Patients must present with at least 3 of the following local signs/symptoms: pain, tenderness, swelling erythema, warmth, drainage/discharge, induration, and lymph node swelling/tenderness. Patients will be randomized 1:1 ceftaroline or vancomycin with optional anaerobic and/or Gram-negative coverage. The assignment of study drug will follow a randomized list that was previously generated via a computerized random mix block generator (nQuery Advisor® 7.0) and available at each of the study sites. Patients will be randomized to ceftaroline intravenously at 600 mg infused over 1 hour every 12 hours for patients with normal renal function. Patients randomized to vancomycin will receive the standard 15 mg/kg dose based on total body weight infused over 1 hour q 12 hour, dose and interval adjusted based on creatinine clearance and via institution-specific pharmacy protocol to target serum trough concentrations of 10-20 mg/L within the first 72 hours. Outcomes measured in the Clinically Evaluable patient population include day two or three size reduction (percentage) and clinical response at end of therapy or discharge.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00746109 -
Study of Wound Packing After Superficial Skin Abscess Drainage
|
Phase 4 | |
Completed |
NCT00210899 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT00761215 -
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
|
Phase 2 | |
Completed |
NCT00228982 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT01967225 -
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
|
Phase 3 | |
Withdrawn |
NCT00990392 -
Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections
|
N/A | |
Completed |
NCT00228410 -
Study Comparing Tigecycline and Vancomycin With Aztreonam in Complicated Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT05608382 -
Effect of an Antiseptic Solution on the Skin Microbiome
|
N/A | |
Completed |
NCT03487549 -
Cantharidin and Occlusion in Verruca Epithelium
|
Phase 2 | |
Completed |
NCT02276482 -
Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)
|
Phase 3 | |
Completed |
NCT00198679 -
Effect of Chlorhexidine Skin Cleansing on Skin Flora
|
Phase 4 | |
Completed |
NCT03981822 -
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
|
Phase 2 | |
Completed |
NCT00711802 -
Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
|
Phase 4 | |
Completed |
NCT00679302 -
Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management
|
Phase 4 | |
Completed |
NCT00488761 -
Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI
|
Phase 4 | |
Completed |
NCT00257036 -
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin
|
Phase 2/Phase 3 | |
Completed |
NCT04485676 -
Dalbavancin in Real Clinical Practice in Spain
|
||
Completed |
NCT00785200 -
MRSA Colonization and Control in the Dallas County Jail
|
N/A | |
Completed |
NCT00257062 -
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Uncomplicated Infections of the Skin and the Supportive Layers Beneath the Skin
|
Phase 3 | |
Completed |
NCT00388310 -
Effective Antibiotic Treatment of MRSA
|
N/A |